BeStock  
Stocks › Biotechnology › ERAS

Erasca ERAS

US equityMarket cap rank #2084Biotechnology
$13.61 −$0.61 (-4.29%)
Market closed · Nov 20, 8:20 pm ET · Last extended-hours $13.74 +0.96%
Open$13.13
Prev close$14.22
Day range$13.13 – $14.31
Volume11.07M
Market cap$4.78B
P/E (TTM)–
Dividend yield–

Ownership & positioning

Who holds it, who is betting against it, and where the big money is moving

Institutional ownership89.4%-1.52 pts vs. prior quarter
Institutions holding309+15 vs. prior quarter
Insider trades (recent)38 buys / 12 sellsNet buying
Short interest10.62% of floatDays to cover 8.9 · as of 30 Oct 2026
Short-sale volume share26.2%5-day average of daily volume

Short-sale volume as % of daily volume

12%21%30%39%Oct '26Oct '26Nov '26

Large-order net flow, last 20 sessions

Net of large-order buying minus selling, in USD. Over this window: −$21.06M (7 inflow days, 13 outflow days).

Net flow by order size, last 20 sessions

−$20.3MSuper−$766.2KBig+$4.9MMid+$6.6MSmall

Super/Big orders approximate institutional-size trades; Mid/Small approximate retail-size trades. Net buy minus sell value in each bucket, summed over the window.

The five largest holders on file together own 36.2% of shares outstanding.

Largest holders

  • Jonathan Lim9.25%
  • T. Rowe Price Group, Inc.7.85%
  • Frazier Life Sciences Management, LP7.14%
  • BlackRock6.79%
  • RTW Investments, LP5.13%
  • VR Management, LLC5.12%
  • Vanguard Capital Management, LLC3.98%
  • State Street Global Advisors3.95%

By investor type

  • Mutual Fund41.86%
  • Hedge Fund22.47%
  • VC/PE Fund20.59%
  • Individual/Insider9.65%
  • Public Company2.47%
  • Private Company0.76%
  • Sovereign Wealth Fund0.60%
  • Insurance Company0.43%

Reported short interest has risen from 8.82% to 10.62% of float over the last 6 biweekly reports (14 Aug 2026 to 30 Oct 2026).

Recent institutional activity

HolderTypePeriodShare changeNew stake
Capital Research Mutual Fund 2026/Q3 +8,656,799 2.7%
Vanguard Portfolio Management, LLC Mutual Fund 2026/Q3 +6,060,267 2.4%
Assenagon Asset Management S.A. Mutual Fund 2026/Q3 +3,315,456 1.2%
BlackRock Mutual Fund 2026/Q3 +2,581,932 6.8%
Vanguard Capital Management, LLC Mutual Fund 2026/Q3 +2,503,597 4.0%
Artal Group S.A. VC/PE Fund 2026/Q3 +1,800,000 3.8%
State Street Global Advisors Mutual Fund 2026/Q3 +1,637,088 4.0%
UBS Asset Management Mutual Fund 2026/Q3 +1,137,925 0.9%
T. Rowe Price Group, Inc. Mutual Fund 2026/Q3 +4,383,361 7.9%
State Street Global Advisors Mutual Fund 2026/Q3 +2,884,471 3.5%
Jennison Associates LLC Mutual Fund 2026/Q3 +2,788,412 0.8%
Soleus Capital Management, L.P. Hedge Fund 2026/Q3 +2,700,000 0.8%
Samlyn Capital, LLC Hedge Fund 2026/Q3 +2,256,986 0.6%
Norges Bank Investment Management Sovereign Wealth Fund 2026/Q3 +2,114,390 0.6%
RTW Investments, LP Hedge Fund 2026/Q3 +1,789,579 5.1%

Institutional buy/sell activity by reporting period, largest moves first.

Insider transactions

DateInsiderTitleTransactionSharesPriceHeld after
9 Aug 2026 Charles Fuchs President of Research & Development Other Derivative Acquisition +1,300,000 $18.12 1,300,000
25 Jun 2026 Jean I. Liu Independent Director Other Derivative Acquisition +29,888 $16.01 29,888
25 Jun 2026 Alexander Casdin Independent Director Other Derivative Acquisition +29,888 $16.01 29,888
25 Jun 2026 Pratik Multani Independent Director Other Derivative Acquisition +29,888 $16.01 29,888
25 Jun 2026 James Bristol Lead Independent Director Other Derivative Acquisition +29,888 $16.01 29,888
25 Jun 2026 Julie Hambleton Independent Director Other Derivative Acquisition +29,888 $16.01 29,888
25 Jun 2026 Valerie Harding-Start Independent Director Other Derivative Acquisition +29,888 $16.01 29,888
31 Mar 2026 Ebun Garner Chief Legal Officer Derivative Exercise and Sale -80,000 $16.40 25,076
3 Mar 2026 Shannon Morris Chief Medical Officer Derivative Exercise and Sale -20,000 $15.04 –
28 Jan 2026 Michael Varney Chairman of Research & Development, Scientific Advisory Board Member and Director Other Derivative Acquisition +96,000 $10.31 96,000
28 Jan 2026 Jonathan Lim Chairperson & CEO Other Derivative Acquisition +2,000,000 $10.31 2,000,000
28 Jan 2026 Ebun Garner Chief Legal Officer Other Derivative Acquisition +560,000 $10.31 560,000
28 Jan 2026 Shannon Morris Chief Medical Officer Other Derivative Acquisition +625,000 $10.31 625,000
28 Jan 2026 David Chacko CFO & Chief Business Officer Other Derivative Acquisition +640,000 $10.31 640,000
6 Jan 2026 Ebun Garner Chief Legal Officer Derivative Exercise and Sale -120,000 $5.59 25,076
31 Dec 2025 Jean I. Liu Independent Director Other Derivative Acquisition +20,617 $3.72 20,617
31 Dec 2025 Alexander Casdin Independent Director Other Derivative Acquisition +23,872 $3.72 23,872
31 Dec 2025 Pratik Multani Independent Director Other Derivative Acquisition +19,532 $3.72 19,532
31 Dec 2025 James Bristol Lead Independent Director Other Derivative Acquisition +37,762 $3.72 37,762
31 Dec 2025 Valerie Harding-Start Independent Director Other Derivative Acquisition +24,306 $3.72 24,306

From Form 4/Form 144 filings. Negative share counts are disposals (sales, gifts, or shares withheld for taxes); positive are acquisitions.

Short interest, by report

Report dateShares short% of floatDays to cover
30 Oct 2026 37,156,627 10.6% 8.9
15 Oct 2026 36,963,404 10.6% 6.4
30 Sep 2026 35,338,107 10.1% 6.9
15 Sep 2026 33,036,139 9.4% 7.7
31 Aug 2026 31,238,099 8.9% 9.4
14 Aug 2026 30,847,289 8.8% 10.0

Discussion

No comments yet — be the first to weigh in on ERAS.

Sign in to join the discussion.

Scroll to Top